바이오스펙테이터

바이오스펙테이터 Jongwon Jang 기자

In Europe, Celltrion’s biosimilar, Remsima, has exceeded the market share of the Remicade, the original biologic from Johnson & Johnson. Truxima, another biosimilar from Celltrion, is expanding its impact with high market share in Netherlands and the UK.

According to Celltrion Healthcare and market researcher IQVIA on 28th, Resima achieved 52% market share (based on vials) in Europe in the fourth quarter of 2017. It is the first ever time that biosimilars have surpassed the market share of original drugs.

Remsima from Celltrion was marketed in August 2013 with marketing approval froom European Medicines Agency (EMA). In 2015, the market share rose sharply as it was sold in major countries such as Germany, Italy, Spain, and the United Kingdom. The company maintained its 40% market share by early last year, and has exceeded its original drug, Remicade, in the fourth quarter of 2017.

Truxima had launched in the second quarter last year, and has showed explosive growth in the fourth quarter with a market share of 58% in the Netherlands. Truxima has achieved a market share of 43% in the UK and has steadily increased its market share with a market share of 16% in five major European countries such as Germany, France, Spain, and Italy.

Celltrion Healthcare currently sells ‘Truxima’ in 12 countries in Europe and plans to expand its sales territories throughout the entire Europe this year.

Celltrion Healthcare officials said, “Based on our marketing know-how accumulated through our sales experience for many years, and our distribution partners' experience in global partners, we are doing customized sales marketing activities for each country that differentiate us from competitors. Plentiful clinical data, drug supply stability, and other business strengths of the Celltrion Group contribute to a great factor makes settling down easy and fast to the market. "

On the other hand, Celltrion Healthcare is finalizing the launch and marketing plan for 'Herzuma' with the aim of participating in large-scale pharmaceutical bidding for 'Herzuma' (ingredient name: Trastuzumab) scheduled for the second quarter this year with distribution partners.

Celltrion Healthcare said, "Herzuma, which is about to enter full-fledged sales soon, is expected to follow a growth track similar to 'Remsima' and 'Truxima' in Europe. We are planning more active and aggressive marketing activities this year, hoping the earlier success with Remsima and Truxima to be continued with Herzuma."